<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477542</url>
  </required_header>
  <id_info>
    <org_study_id>0704-30 IUCRO-0186</org_study_id>
    <nct_id>NCT00477542</nct_id>
  </id_info>
  <brief_title>A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT</brief_title>
  <official_title>A Phase I Trial of Myeloablative Conditioning Using Clofarabine and High-Dose Busulfan for Patients With Refractory Hematological Malignancies Undergoing Allogeneic HSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase trial to determine the maximum tolerated dose (MTD) of clofarabine in a&#xD;
      combination with a myeloablative dose of busulfan. This is an initial step in developing a&#xD;
      novel myeloablative preparative regimen for allogeneic hematopoietic stem cell&#xD;
      transplantation (HSCT). While this phase I trial will initially develop the regimen in&#xD;
      patients with refractory disease, it is expected that it will find its best application in&#xD;
      patients with less advanced disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive the same dose of busulfan. The dose of clofarabine will be&#xD;
      escalated in successive cohorts of patients. Using a standard dose escalation design,&#xD;
      successive cohorts of 3 patients will be treated with escalating doses of clofarabine. At the&#xD;
      MTD (or highest dose-level if the MTD is not reached), the cohort will be expanded to 10&#xD;
      patients to better investigate correlative studies and give some preliminary idea of&#xD;
      efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the MTD of clofarabine in association with a myeloablative dose of busulfan as a preparative regimen in patients with refractory hematological malignancies undergoing allogeneic HSCT.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Assessment of the toxicity of the combination of clofarabine and busulfan • Assess clofarabine and busulfan pharmacokinetics with combination therapy • Describe the response rate • Describe relapse rate and event-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Hematologic Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
    <description>Cohort- n- Clofarabine (mg/m2/day)&#xD;
-1 3-10 20&#xD;
3-6 30&#xD;
3-6 40&#xD;
3-6 50&#xD;
3-6 60&#xD;
6-10 70</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documentation of disease. Patients must have one of the following disease types:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) with either:&#xD;
&#xD;
                    -  Primary refractory to induction chemotherapy&#xD;
&#xD;
                    -  Relapsed and refractory AML with &gt;5% blasts in bone marrow or extramedullary&#xD;
                       disease (excluding active disease of the central nervous system).&#xD;
&#xD;
                    -  Patients in second or subsequent complete remission (CR2, CR3, etc.).&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL) with one of the following criteria:&#xD;
&#xD;
                    -  Primary refractory to induction chemotherapy.&#xD;
&#xD;
                    -  Relapsed and refractory ALL with &gt;5% blasts in bone marrow or extramedullary&#xD;
                       disease (excluding active disease of the central nervous system).&#xD;
&#xD;
                    -  Patients in second or subsequent complete remission (CR2, CR3, etc.).&#xD;
&#xD;
               -  Myelodysplasia, refractory anemia with excess blasts with 11-20% blasts in the&#xD;
                  bone marrow (RAEB II).&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML) with one of the following criteria:&#xD;
&#xD;
                    -  Accelerated phase.&#xD;
&#xD;
                    -  Patients in blast crisis.&#xD;
&#xD;
               -  Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large&#xD;
                  cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell&#xD;
                  lymphoma, and peripheral T cell lymphoma, who also have one of the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  Failure to achieve complete remission to primary induction therapy&#xD;
&#xD;
                    -  Relapsed NHL, refractory to at least one line of salvage systemic therapy&#xD;
&#xD;
          -  Patients who relapse &lt; 6 months following autologous stem cell transplantation are not&#xD;
             eligible.&#xD;
&#xD;
          -  Patient age 18-60 years&#xD;
&#xD;
          -  Availability of a consenting HLA-matched donor&#xD;
&#xD;
          -  Performance status ECOG 0-1&#xD;
&#xD;
          -  No active infection. Patients with active infections requiring oral or intravenous&#xD;
             antibiotics are not eligible for enrollment until resolution of infection.&#xD;
&#xD;
          -  No HIV disease. Patients with immune dysfunction are at a significantly higher risk of&#xD;
             infection from intensive immunosuppressive therapies.&#xD;
&#xD;
          -  Non-pregnant and non-nursing. Treatment under this protocol would expose a fetus to&#xD;
             significant risks. Women of childbearing potential should have a negative pregnancy&#xD;
             test prior to study entry. Women and men of reproductive potential should agree to use&#xD;
             an appropriate method of birth control throughout their participation in this study&#xD;
             due to the teratogenic potential of the therapy utilized in this trial. Appropriate&#xD;
             methods of birth control include oral contraceptives, implantable hormonal&#xD;
             contraceptives (Norplant®), or double barrier method (diaphragm plus condom).&#xD;
&#xD;
          -  Required baseline laboratory values:&#xD;
&#xD;
               -  LVEF &gt; 45% corrected&#xD;
&#xD;
               -  DLCO &gt; 50% of predicted value (corrected for hemoglobin)&#xD;
&#xD;
               -  Serum creatinine ≤ 2.0 mg/dl or estimated creatinine clearance of ≥60 ml/min&#xD;
&#xD;
               -  Bilirubin &lt; 1 x upper limit of normal value&#xD;
&#xD;
               -  AST and ALT &lt; 1 x upper limit of normal value&#xD;
&#xD;
          -  Signed written informed consent. Patient must be capable of understanding the&#xD;
             investigational nature of the investigational nature, potential risks and benefits of&#xD;
             the study, and able to provide valid informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who relapse &lt; 6 months following autologous stem cell transplantation are not&#xD;
             eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif Farag, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>May 21, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2007</study_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clofarabine</keyword>
  <keyword>allogeneic HSCT</keyword>
  <keyword>refractory malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

